A gene-editing tool called CRISPR holds promise for treating cancer. What does the new technology mean for patients?
by Stephen Ornes
Following the arrival of the coronavirus in the U.S., people with cancer and their doctors are adjusting to new ways of doing things while continuing to seek and provide cancer care.
COVID-19 slowed or stopped enrollment in some cancer clinical trials.
Data shed light on risk factors for death among people with cancer infected with the coronavirus.
I have brain cancer, and my wife is a health care worker. These are some questions we had to consider leading up to and after her diagnosis with COVID-19.
Identifying patients whose cancers will have durable responses to checkpoint inhibitors can guide treatment.
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with metastatic prostate cancer.
Bladder cancer is the sixth most prevalent cancer in the United States and has a high rate of recurrence.
Handle With Care
donate to the AACR
The AACR Cancer Progress Report 2019, which is published annually by the American Association for Cancer Research, tracks recent developments that impact cancer care. Click “Progress Report” below to find out more.